PLCXD2

Across TCGA pan-cancer cohorts, PLCXD2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PLCXD2 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher PLCXD2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PLCXD2 expression acts as an unfavorable survival marker.

ACC, COAD, and UCEC are the cancer types where PLCXD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
COAD	OS	Median	All	0.100	0.809	<.001	27	view →
UCEC	OS	Median	IV	0.225	0.772	<.001	12	view →
SKCM	OS	Median	III,IV	0.179	0.721	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PLCXD2–ACC (DFS)

Open the ACC breakdown →